Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1

Charles Lawrence Loprinzi, Brandi N. Reeves, Shaker R. Dakhil, Jeff A Sloan, Sherry L. Wolf, Kelli N. Burger, Arif Kamal, Nguyet A. Le-Lindqwister, Gamini S. Soori, Anthony J. Jaslowski, Paul J. Novotny, Daniel H Lachance

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated. Methods: Patients receiving weekly paclitaxel (70 to 90 mg/m2) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy. Results: P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy. Conclusion: These data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.

Original languageEnglish (US)
Pages (from-to)1472-1478
Number of pages7
JournalJournal of Clinical Oncology
Volume29
Issue number11
DOIs
StatePublished - Apr 10 2011

Fingerprint

Acute Pain
Paclitaxel
Cohort Studies
Prospective Studies
Pain
Hypesthesia
Drug Therapy
Myalgia
Arthralgia
Peripheral Nervous System Diseases
Natural History
Pathology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Natural history of paclitaxel-associated acute pain syndrome : Prospective cohort study NCCTG N08C1. / Loprinzi, Charles Lawrence; Reeves, Brandi N.; Dakhil, Shaker R.; Sloan, Jeff A; Wolf, Sherry L.; Burger, Kelli N.; Kamal, Arif; Le-Lindqwister, Nguyet A.; Soori, Gamini S.; Jaslowski, Anthony J.; Novotny, Paul J.; Lachance, Daniel H.

In: Journal of Clinical Oncology, Vol. 29, No. 11, 10.04.2011, p. 1472-1478.

Research output: Contribution to journalArticle

Loprinzi, CL, Reeves, BN, Dakhil, SR, Sloan, JA, Wolf, SL, Burger, KN, Kamal, A, Le-Lindqwister, NA, Soori, GS, Jaslowski, AJ, Novotny, PJ & Lachance, DH 2011, 'Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1', Journal of Clinical Oncology, vol. 29, no. 11, pp. 1472-1478. https://doi.org/10.1200/JCO.2010.33.0308
Loprinzi, Charles Lawrence ; Reeves, Brandi N. ; Dakhil, Shaker R. ; Sloan, Jeff A ; Wolf, Sherry L. ; Burger, Kelli N. ; Kamal, Arif ; Le-Lindqwister, Nguyet A. ; Soori, Gamini S. ; Jaslowski, Anthony J. ; Novotny, Paul J. ; Lachance, Daniel H. / Natural history of paclitaxel-associated acute pain syndrome : Prospective cohort study NCCTG N08C1. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 11. pp. 1472-1478.
@article{598bd938fed74bfb8a41195b1e2225dd,
title = "Natural history of paclitaxel-associated acute pain syndrome: Prospective cohort study NCCTG N08C1",
abstract = "The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated. Methods: Patients receiving weekly paclitaxel (70 to 90 mg/m2) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy. Results: P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy. Conclusion: These data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.",
author = "Loprinzi, {Charles Lawrence} and Reeves, {Brandi N.} and Dakhil, {Shaker R.} and Sloan, {Jeff A} and Wolf, {Sherry L.} and Burger, {Kelli N.} and Arif Kamal and Le-Lindqwister, {Nguyet A.} and Soori, {Gamini S.} and Jaslowski, {Anthony J.} and Novotny, {Paul J.} and Lachance, {Daniel H}",
year = "2011",
month = "4",
day = "10",
doi = "10.1200/JCO.2010.33.0308",
language = "English (US)",
volume = "29",
pages = "1472--1478",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Natural history of paclitaxel-associated acute pain syndrome

T2 - Prospective cohort study NCCTG N08C1

AU - Loprinzi, Charles Lawrence

AU - Reeves, Brandi N.

AU - Dakhil, Shaker R.

AU - Sloan, Jeff A

AU - Wolf, Sherry L.

AU - Burger, Kelli N.

AU - Kamal, Arif

AU - Le-Lindqwister, Nguyet A.

AU - Soori, Gamini S.

AU - Jaslowski, Anthony J.

AU - Novotny, Paul J.

AU - Lachance, Daniel H

PY - 2011/4/10

Y1 - 2011/4/10

N2 - The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated. Methods: Patients receiving weekly paclitaxel (70 to 90 mg/m2) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy. Results: P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy. Conclusion: These data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.

AB - The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated. Methods: Patients receiving weekly paclitaxel (70 to 90 mg/m2) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy. Results: P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy. Conclusion: These data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.

UR - http://www.scopus.com/inward/record.url?scp=79955017479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955017479&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.33.0308

DO - 10.1200/JCO.2010.33.0308

M3 - Article

C2 - 21383290

AN - SCOPUS:79955017479

VL - 29

SP - 1472

EP - 1478

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -